Search
Dienogest
go.drugbank.com/drugs/DB09123ApprovedInvestigationalIt is primarily used as a contraceptive in combination with ethinylestradiol, or in other combination form pills approved in United States and Europe however it is not available in the US by itself. … In Europe, Australia, Malaysia, Singapore and Japan, dienogest single therapy is an approved treatment for endometriosis to alleviate painful symptoms of endometriosis and reduce endometriotic lesions
Tofersen
go.drugbank.com/drugs/DB14782ApprovedInvestigational[L52735] Tofersen demonstrated efficacy in reducing the concentration of SOD1 in CSF and of neurofilament light chains in plasma over 28 weeks, although the ALS Functional Rating Scale–Revised did not … [L46133] In June of 2024, it was additionally approved by the EMA for the same indication.
Tremelimumab
go.drugbank.com/drugs/DB11771ApprovedInvestigational[A253712] Tremelimumab was first approved by the FDA in October 2022 to be used in combination with [durvalumab] to treat hepatocellular carcinoma. … [A253717, L43652] Because CTLA-4 is an immune checkpoint that plays a vital role in regulating T cell-mediated immune response, tremelimumab is considered an immune checkpoint inhibitor, which is an emerging
Pholcodine
go.drugbank.com/drugs/DB09209ApprovedIllicit[A31742] Pholcodine is not prescribed in the United States where it is classed as a Schedule I drug. It is categorized as Class B drug in the UK and officially taken out of the shelves in 2008. … Pholcodine is not approved in Canada.
Ibrexafungerp
go.drugbank.com/drugs/DB12471Approved[A235384,A235389] Similar to echinocandins, ibrexafungerp targets the fungal β-1,3-glucan synthase, which is not present in humans, limiting the chance of renal or hepatic toxicity. … [A235414,L34349] Ibrexafungerp was granted FDA approval on 1 June 2021.[L34349]
Zilucoplan
go.drugbank.com/drugs/DB15636ApprovedInvestigationalIt is a complement inhibitor that works to prevent the activation of C5, which is a complement protein involved in the innate immune system to initiate inflammatory responses. … [L48701] It was also later approved by the EMA on December 4, 2023, as an add-on treatment for the same condition.[L49131] In July 2024, it was approved by Health Canada for the same indication.
Synonyms: -HYDROXY-, 15-ETHER WITH N-ACETYL-L-LYSYL-L-VALYL-L-.ALPHA.-GLUTAMYL-L-ARGINYL-L-PHENYLALANYL-L-.ALPHA.-ASPARTYL-N-METHYL-L-.ALPHA.-ASPARTYL-3-METHYL-, -ASPARTYL-N-METHYL-L-.ALPHA.-ASPARTYL-3-METHYL-L-VALYL-L-TYROSYL-3-(1H-PYRROLO(2,3-B)PYRIDIN-3-YL)-L-ALANYL-L-.ALPHA.-GLUTAMYL-L-TYROSYL-L-PROLYL-(2S)-2-CYCLOHEXYLGLYCYL-N6-(3Glucarpidase
go.drugbank.com/drugs/DB08898ApprovedInvestigational[L39855] Glucarpidase was first approved by the FDA in January 2012,[A7476] followed by the European Commission's approval in January 2022.[L39865] It is marketed as VORAXAZE. … In 1983, the gene for carboxypeptidase G2, or glucarpidase, was derived from _Pseudomonas_ sp. strain RS-16 to be cloned into _Escherichia coli_, allowing the enzyme to be produced in sufficient quantities
Magnesium cation
go.drugbank.com/drugs/DB01378ApprovedInvestigationalNutraceuticalWithdrawnMagnesium hydroxide is used primarily in "Milk of Magnesia", a white aqueous, mildly alkaline suspension of magnesium hydroxide formulated at about 8%w/v. … draw fluids from the body and to retain those already within the lumen of the intestine, serving to distend the bowel, thus stimulating nerves within the colon wall, inducing peristalsis and resulting in
Mixtures: KALSİMAG-D3 1000 MG/300 MG/880 IU EFERVESAN GRANÜL, 30 ADET, KALSİMAG-D3 1000 MG/300 MG/880 IU EFERVESAN GRANÜL, 40 ADETCategories: Magnesium Ion Exchange ActivityRilonacept
go.drugbank.com/drugs/DB06372ApprovedInvestigationaland Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old. … Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS)
Synonyms: IL-1 TRAP, IL-1-TRAPCategories: Receptors, Interleukin-1 Type IAlectinib
go.drugbank.com/drugs/DB11363ApprovedInvestigationalApproved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance … It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC